Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Cystic FibrosisExocrine Pancreatic Insufficiency
Interventions
DRUG

EUR-1008 (APT-1008)

EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).

Trial Locations (14)

26506

West Virginia Health Sciences Center, Morgantown

32250

Nemours Childrens Clinic, Jacksonville

35294

University of Alabama, Birmingham

45229

Children's Hospital Medical Center, Cincinnati

48109

University of Michigan, Cystic Fibrosis Center, Ann Arbor

52242

University of Iowa, Iowa City

60614

Childrens Memorial Hospital, Chicago

75708

University of Texas, Tyler

84108

University of Utah, Salt Lake City

90027

Children's Hospital of Los Angeles, Los Angeles

92123

Children's Hospital of San Diego, San Diego

94304

Stanford University Medical Center, Palo Alto

94609

Children's Hospital - Oakland, Oakland

32610-0296

University of Florida College of Medicine, Gainsville

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY